NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS EBITDA Margin

EBITDA as a percentage of revenue.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -1613.7%

EBITDA Margin was -1613.7% in Q2 FY2026, down 1523.3 pp from a year earlier. On a trailing-twelve-month basis it was -3579.7%, down 3279.2 pp year over year. Over 3 fiscal years it narrowed by 1055.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -458.3% for the fiscal year ending Dec 2026, up from -1076.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-1613.7%-22.3 pp QoQ
Last fiscal yearDec 2025
-1076.9%-546.9 pp YoY
LTMJun 2026
-3579.7%-3279.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1523.3 pp+20009.5 pp+21532.7 pp
1 year-546.9 pp+618.6 pp+1165.5 pp
3 years-1055.1 pp+1028.6 pp+2083.7 pp
5 years+1112.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1076.9%
Year-over-year change
-546.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NAMS compares with its peers on the latest reported figures

  • NAMS's LTM Jun 2026 EBITDA Margin of -3579.7% is the 5th highest of the 6 companies compared; the peer median is -269.0%.
  • Its year-over-year change of -3279.2 pp is the lowest of 5, against a peer median of +250.4 pp.
  • Over three fiscal years its change of -1055.1 pp compares with a peer median of +70.4 pp.
NAMS Competitors Peer median
EBITDA Margin for NAMS and competitors
Company Period LTM level YoY 3-year change
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026-22.7% +29.0 pp—
SEPNSepterna, Inc.LTM Sep 2026-59.3% +282.9 pp—
ATHEAlterity Therapeutics LimitedFY2025-269.0% +217.9 pp+70.4 pp
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-3579.7% -3279.2 pp-1055.1 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-13823.7% ——
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
VKTXViking Therapeutics, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NAMS) -269.0%+250.4 pp+70.4 pp

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.